Isotretinoin increases skin-surface levels of neutrophil gelatinase-associated lipocalin in patients treated for severe acne
Summary Background A clear‐cut need exists for safe and effective alternatives to the use of isotretinoin in severe acne. Lack of data regarding the specifics of isotretinoin’s mechanism of action has hampered progress in this area. Recently, the protein neutrophil gelatinase‐associated lipocalin (...
Saved in:
Published in | British journal of dermatology (1951) Vol. 165; no. 2; pp. 302 - 310 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford, UK
Blackwell Publishing Ltd
01.08.2011
Wiley-Blackwell |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Summary
Background A clear‐cut need exists for safe and effective alternatives to the use of isotretinoin in severe acne. Lack of data regarding the specifics of isotretinoin’s mechanism of action has hampered progress in this area. Recently, the protein neutrophil gelatinase‐associated lipocalin (NGAL) has been identified as a mediator of the apoptotic effect of isotretinoin on sebocytes.
Objectives To establish further the clinical relevance of NGAL and to elucidate the factors that induce NGAL expression in sebocytes.
Methods Methods were developed to isolate and quantify skin‐surface levels of NGAL from normal subjects and patients with acne undergoing treatment with isotretinoin.
Results Patients with acne were found to have higher skin levels of NGAL compared with normal subjects. Studies in SEB‐1 sebocytes indicate that NGAL expression is increased in response to Propionibacterium acnes and interleukin (IL)‐1β. In patients, isotretinoin increases NGAL levels by 2·4‐fold on the skin surface and this increase precedes decreases in sebum and P. acnes counts.
Conclusions These data support the hypothesis that NGAL is an important mediator of the early effects of isotretinoin on the sebaceous glands and provide insights into the mechanisms that regulate NGAL expression in the skin. |
---|---|
Bibliography: | ark:/67375/WNG-LPN39NVZ-5 ArticleID:BJD10362 istex:ACDDA9221C109BEA29C2B4779A39C391CA51A276 Funding sources This work was supported by NIH NIAMS grants F31AR054723‐01 to K.R.L., RO1AR047820 to D.M.T., NIH General Clinical Research Center grants M01RR010732 and C06RR016499 to The Pennsylvania State University College of Medicine and the Jake Gittlen Cancer Research Foundation at the Pennsylvania State University College of Medicine. Conflicts of interest None declared. Present address of A.M. Nelson: Department of Dermatology, Johns Hopkins School of Medicine, Baltimore, MD 21231, U.S.A. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 current address: Johns Hopkins School of Medicine, Department of Dermatology, Baltimore, MD 21231. |
ISSN: | 0007-0963 1365-2133 1365-2133 |
DOI: | 10.1111/j.1365-2133.2011.10362.x |